Unbiased Analysis of Today's Healthcare Issues
Below is an abstract from on of my recent studies on patient and physician preferences for treatments for nonvalvular atrial fibrillation. The full article is HERE. Objectives The objective of this study was to compare patient and physician preferences for different antithrombotic therapies used to treat nonvalvular atrial fibrillation (NVAF). Methods Patients diagnosed with NVAF…
You can find one of my recent papers measuring how well survival measures from clinical trials (i.e., overall survival, progression free survival, time to progression) translate into real-world survival outcomes in Current Medical Research and Opinion here. The abstract is below. Objective It is unclear how well different outcome measures in randomized controlled trials (RCTs) perform in…
If you are attending AMCP Nexus in October, I am a co-author on a poster presentation titled “The Cost of Adherence Mismeasurement: A Claims-Based Analysis” co-authored with Felicia Forma, Ethan Scherer, Ainslie Hatch and Darius Lakdawalla. The presentation abstract is below and here. BACKGROUND: Payers often wish to measure how adherence to prescription drugs affects downstream…
If you are attending AMCP Nexus in October, I am a co-author on a poster presentation titled “Adherence Patterns for Oral Atypical Antipsychotics in Patients Diagnosed with Schizophrenia” co-authored with Joanna MacEwan, Felicia Forma, Ainslie Hatch and Darius Lakdawalla. The presentation abstract is below and here. BACKGROUND: Many payers rely on claims-based metrics—such as those…
The health care industry should take into account outcomes when weighing the cost of new treatments and technologies and make quality-adjusted life years (QALYs) part of the equation, say the authors of a study in the April issue of Health Affairs. This is the begining of an article in Managed Care Magazine that reviews a…
One of my paper (along with co-authors Darius Lakdawalla, Claudio Lucarelli, Sean Nicholson, Zeba M. Khan and Tomas J. Philipson) was published at Health Affairs. The title of the study is: Quality-Adjusted Cost Of Care: A Meaningful Way To Measure Growth In Innovation Cost Versus The Value Of Health Gains. The abstract is below. Technology drives both…
Next month in San Diego, the Academy of Managed Care Pharmacy is holding its annual conference. I am a co-author on two abstracts accepted as part of the conference. The first abstract won a platinum medal as one of the top 7 abstracts in the entire conference, the second abstract won a silver medal as well. The titles…
I am excited to announce that as of April 5, 2013, I will be joining the firm Precision Health Economics. PHE is a leading health care consulting company providing sophisticated quantitative analysis. More information on the firm is below: In 2005, a group of academic health economists from elite research universities founded Precision Health Economics…
The Healthcare Economist has a new report out for the Institute of Medicine. The report is co-authored with a number of outstanding individuals at Acumen including: Thomas MaCurdy, Jay Bhattacharya, Daniella Perlroth, Anita Au-Yeung, Hani Bashour, Camille Chicklis, Kennan Cronen, Brandy Lipton, Shahin Saneinejad, Elen Shrestha, and Sajid Zaidi. IOM summarizes the goals of the…
Medicare’s Hospital Compare website evaluates hospital quality. One of the most recent measures to be added to Hospital Compare is a measure of efficiency. The measure calculates a price-standardized, case-mix adjusted measure of spending during period before, during and after a hospital admission. The Healthcare Economist (Jason Shafrin) and a team at Acumen (including Tom…